drugset / Trial / NCT00784446
First-line Therapy of Stage IV Colorectal Cancer
Phase 1/2
Completed
51 enrolled
University of Cologne
Novartis · collabRoche Pharma AG · collabSanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Assessment of safety and toxicity, definition of the dose limiting toxicity (DLT) of the combination therapy consisting of Capecitabine, Oxaliplatin, Bevacizumab and Imatinib.
Timeline
- Start
- 2008-04
- Primary completion
- 2010-08
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Comparator | Capecitabine | Small molecule | 800 mg/m2 | Oral |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Imatinib | Small molecule | 300 mg | Oral |
| Comparator | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | — |